 "Aurobindo Pharma gains on good Q4 results")
Aurobindo Pharma has moved higher by 5% to Rs 795 on the BSE in noon deals after the company reported 39% year on year (YoY) jump in consolidated net profit at Rs 563 crore for the quarter ended March 2016 (Q4FY16) on the back of healthy growth in net sales. Consolidated revenues grew 19% YoY at Rs 3,747 crore on YoY basis.
Analysts on an average had expected profit of Rs 556 crore on revenues of Rs 3,713 crore for the quarter.
Ebitda (earnings before interest, taxes, depreciation and amortization) margin before forex improved 280 basis points to 23.5% from 20.7%.
“The company’s US formulations contributed 44% to the total revenues, witnessed 24.3% growth YoY in Q4FY16, due to the new launches in the oral and injectable segment and growth in the Natrol business,” Aurobindo Pharma said in a release.
EU formulations, which contributed 22% to the total revenues, registered 9.3% growth YoY during the quarter. The acquired business has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies, it added.
At 01:42 PM, the stock was up 4.5% at Rs 789 on the BSE. A combined 3.23 million shares changed hands on the counter on the BSE and NSE.
Analysts on an average had expected profit of Rs 556 crore on revenues of Rs 3,713 crore for the quarter.
Ebitda (earnings before interest, taxes, depreciation and amortization) margin before forex improved 280 basis points to 23.5% from 20.7%.
“The company’s US formulations contributed 44% to the total revenues, witnessed 24.3% growth YoY in Q4FY16, due to the new launches in the oral and injectable segment and growth in the Natrol business,” Aurobindo Pharma said in a release.
EU formulations, which contributed 22% to the total revenues, registered 9.3% growth YoY during the quarter. The acquired business has seen profitability during the year on the back of increased focus, product pruning and cost efficiencies, it added.
At 01:42 PM, the stock was up 4.5% at Rs 789 on the BSE. A combined 3.23 million shares changed hands on the counter on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%